CHICAGO: Men undergoing testosterone-lowering therapy for prostate cancer are twice as likely to develop Alzheimer’s disease, a new study revealed.
Androgens are male hormones that play a key role in stimulating prostate cell growth.
And as a result, therapies that suppress androgen activity are a common treatment for prostate cancer.
However, low levels of testosterone may weaken the aging brain’s resistance to Alzheimer’s, experts warned.
Men who take androgen deprivation therapy (ADT) are twice as likely to be diagnosed with Alzheimer’s in the years that follow treatment, than those who don’t undergo the therapy, researchers found.